[{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"14","companyTruncated":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD"}]

Find Clinical Drug Pipeline Developments & Deals for Fonadelpar

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.

                          Brand Name : SJP-0035

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 23, 2024

                          Lead Product(s) : Fonadelpar

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : SENJU PHARMACEUTICAL CO LTD

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank